

AHI Quarterly summary

Advanced Human Imaging Ltd (ASX: AHI) (NASDAQ: AHI) ('AHI' or 'the Company') is pleased to release its Appendix 4C and to provide its shareholders with an update on its activities for the quarter ended 30 June 2022.

Commenting on the June quarter, Mr Vlado Bosanac, Strategy Lead, said:

"The Company has focused over the June quarter on working with its existing partners and the technical support they require with their integrations and go to market strategy. AHI continued assisting multiple partners with the integration of the BodyScan and FaceScan capabilities. Additionally, AHI is pleased to note that the digital health market as a whole has continued to grow with Amazon recently acquiring One Medical for a reported \$3.9 billion, along with IBM Watson's acquisition by San Fransisco partners, is showing a strong forward interest in the digital health market.

As many investors are no doubt aware, the AHI share price has been under significant pressure over the past few months with the new strains of COVID-19 and increasing inflation across the globe creating further concerns. This has affected the market as a whole and AHI has unfortunately been affected like many other listed companies.

AHI remains focused on executing its plans to grow awareness and partnerships across the globe. There are challenges which AHI must face which it will overcome in due course as the world is beginning to open up allowing the Company's partners to access critical skills and funding that has been more difficult through these times. AHI's partners remain firmly in place and the Company is assisting them where required.

AHI's strategic objectives, the quality of its technology and the Company's potential has not changed. AHI has an incredibly strong foundation from which it will launch this next phase of its growth plans".

Vertica Health

With the Vertica integration nearing completion at the end of the June quarter, AHI is looking forward to updating shareholders with completion and launch dates, which remain on target as stated in the March quarterly. Vertica Solution and market-ready designs have target launches during the second half of 2022 and into 2023. Vertica is planning to conclude the integration of the AHI CompleteScan SDK in Q2 2022 into their solution suite.

Activate Health OÜ

Activate Health OÜ ("Activate") integration was close to completion at the close of the June quarter. Activate is planning an initial launch in August to a closed user group within the Ülemiste smart city. Targeting 4,000 initial users across Estonia.

Inter-Psy

Inter-Psy advised prior to the close of the June quarter that their integration kick off meeting was scheduled for 14 July. They will connect their development team with the AHI team to effect the integration. From there they need to complete the design of the UX/UI experience and then complete the front – back end integration. They outlined some minor delays that had now been overcome.

Nextmedicall S.A.C

Integration has been completed and the first pilot is underway. The feedback from Nextmedicall was that the pilot was very positive, however yet to receive the report with the final data and outcomes.

Bizbaz

BizBaz has experiaed delays due to internal staff turn over, with a new CTO appointed in mid June. AHI is working with Bizbaz and hope to have further news for shareholders as soon as possible.

UPDATE ON PRODUCT LAUNCHES

AHI is currently working with a number of its announced partners and assisting them with their requirements in meeting the integration and launch timelines, the current status of these companies are as follows.

Tinjoy

Tinjoy's situation has remained the same with rolling lockdowns due to the zero-COVID-tolerance policy enforcement throughout China. This has meant the call centre has not been operating throughout the quarter, which is the driving force behind the application's marketing to the previously reported pre-registrations.

Nexus-Vita

The Nexus-Vita application experienced further delays in the June quarter due to scope creep and new functionality requests from the the company. Blue Sky Labs worked closely with AHI throughout the quarter and we are now confident the application is nearing sign off.

CASHFLOW UPDATE

As at 30 June 2022, AHI had \$5.978 million cash at Bank, as reported in the attached Appendix 4C.

As foreshadowed in the last quarterly update, the reported net cash used in operating activities eased back from \$3.247 million in the March quarter, to \$1.855 million in the June quarter. No investing or financing activities were reported in the June quarter.

ASX Code: AHI ABN 85 602 111 115 CORPORATE STRUCTURE Issued Capital: ~166.7M Options Issued: ~6.5M Perform Rights: ~15.1M Share price: \$0.12 (29 July 2022)	CORPORATE DIRECTORY <i>Non-Executive Directors</i> Nick Prosser - Chairman Mike Melby Dato Low Koon Poh Peter Goldstein <i>Executive Director, CEO</i> Dr Katherine Iscoe <i>Company Secretary, CFO</i> Simon Durack JP	CONTACT DETAILS Unit 5, 71-73 South Perth Esplanade, South Perth, WA 6151 PO Box 190 South Perth, WA 6951 investors@ahi.tech www.ahi.tech
---	---	--

Forward-Looking Statements:

This document may include forward-looking statements. Forward-looking statements include, but are not limited to, statements concerning Advanced Human Imaging Ltd's planned partner integrations, forecast partner revenue, and other statements that are not historical facts. When used in this document, the words such as "could", "plan", "estimate", "expect", "intend", "may", "potential", "should", and similar expressions are forward-looking statements. Although Advanced Human Imaging Limited believes that its expectations reflected in these forward-looking statements are reasonable, such statements involve risks and uncertainties and no assurance can be given that actual results will be consistent with these forward-looking statements.

About Advanced Human Imaging:

AHI has developed and patented a proprietary dimensioning technology that enables its partners and their users to check, track, and assess their vital signs and dimensions using only a smartphone both privately and accurately.

AHI's goal is to assist our partners by empowering their consumers with this capability. This in return gives its partners the ability to assess, assist, and communicate outcomes with their consumers when navigating day to day life and the ongoing fight against chronic disease which accounts for 86% of global healthcare costs.

Whether this is a personal journey to better health, understanding the risk associated with physical condition, tracking the changes they are experiencing through training, dieting, or under medical regimes, or simply wanting to be correctly sized for a garment when shopping online. The AHI technology delivers this seamlessly, privately, and cost-effectively in only a few minutes.

AHI's partners benefit from its software as a service pricing solution, that reduces with scale. Integration is made easy with the AHI modular system, based on multiple software development kits (SDKs), allowing a partner to select the functions, measurements, and displays to suit their individual needs.

AHI has developed this capability by leveraging the power of Computer Vision, Machine Learning, and patented algorithms, to process these images on secure, enterprise-level infrastructure, delivering an end-to-end experience that is unrivalled in the industry. AHI simplifies the collection of measurements and removes the human error present in traditional methods.

For more information please visit: www.ahi.tech

Approved for release by the Board of Directors.

For more information contact:

Dr Katherine Iscoe,
Chief Executive Officer
Advanced Human Imaging Ltd
E: investors@ahi.tech

Simon Durack JP,
Company Secretary & CFO
Advanced Human Imaging Ltd
E: investors@ahi.tech

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Advanced Human Imaging Ltd

ABN

85 602 111 115

Quarter ended ("current quarter")

30 June 2022

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	22	267
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	(3)	(195)
(d) leased assets	-	-
(e) staff costs	(942)	(4,034)
(f) administration and corporate costs	(889)	(4,890)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	(43)	(100)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	890
1.8 Other (provide details if material)		
1.9 Net cash from / (used in) operating activities	(1,855)	(8,062)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	(3,199)
(b) businesses	-	-
(c) property, plant and equipment	-	(97)
(d) investments	-	-
(e) intellectual property	-	(16)
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	(401)
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	(3,713)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	14,336
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	1,100
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	700
3.6	Repayment of borrowings	-	(687)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (Call Option Control Account)	-	75
3.10	Net cash from / (used in) financing activities	-	15,524

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	7,833	2,229
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,855)	(8,062)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	(3,713)

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	15,524
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	5,978	5,978

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	5,922	6,877
5.2	Call deposits	56	956
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	5,978	7,833

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	(9)
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

Quarterly cash flow report for entities subject to Listing Rule 4.7B

7. Financing facilities	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other - Convertible note: Asia Cornerstone Asset Management	-	-
7.4 Total financing facilities	-	-
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	-	

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(1,855)
8.2 Cash and cash equivalents at quarter end (item 4.6)	5,978
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	5,978
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	3.22
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/a	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/a	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/a	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date:29 July 2022.....

Authorised by:By Order of the Board.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.